文献速递慢阻肺睡眠呼吸障碍

无创正压通气对慢阻肺-阻塞性睡眠呼吸暂停重叠综合征患者全因死亡的长期随访研究

[A long-term follow-up study of noninvasive positive pressure ventilation on all-cause mortality in patients with chronic obstructive pulmonary disease-obstructive sleep apnea overlap syndrome].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2023-01-01

该研究前瞻性纳入187例慢阻肺-阻塞性睡眠呼吸暂停重叠综合征(OVS)患者,分为NIPPV组92例与未使用NIPPV组95例,平均随访39(20,51)个月。两组全因病死率无差异(log rank P=0.229),但未使用NIPPV组心脑血管疾病病死率更高(15.8% vs. 6.5%,P=0.045)。年龄、FEV1及慢阻肺急性加重次数是OVS患者全因死亡的独立危险因素。

要点

  • NIPPV未降低OVS患者全因病死率,但可降低心脑血管疾病病死率。
  • 高龄、低FEV1及慢阻肺急性加重次数是OVS全因死亡的独立危险因素。
  • OVS死亡患者气流受限严重,而OSA程度相对较轻。

核心结论

  • 在常规治疗基础上加用NIPPV可降低OVS患者因心脑血管疾病而死亡的风险。
  • 高龄、低FEV1以及慢阻肺急性加重次数是OVS患者死亡的独立危险因素。

研究设计与样本

  • 前瞻性纳入OVS患者187例,分为NIPPV组92例与未使用NIPPV组95例。
  • NIPPV组男85例、女7例,年龄47~80(66.5±8.5)岁;未使用NIPPV组男89例、女6例,年龄45~79(67.4±7.8)岁。
  • 自入组后开始随访,平均随访39(20,51)个月,比较两组全因死亡。

主要发现

  • 两组基线资料比较差异无显著性(均P>0.05),具有可比性。
  • Kaplan-Meier曲线显示两组全因病死率无差异(log rank P=0.229)。
  • 未使用NIPPV组心脑血管疾病病死率更高(分别为15.8%、6.5%,P=0.045)。
  • 年龄(HR为1.067,95%CI:1.017~1.119,P=0.008)、FEV1(HR为0.378,95%CI:0.176~0.811,P=0.013)以及慢阻肺急性加重次数(HR为1.298,95%CI:1.102~1.530,P=0.002)是OVS患者死亡的独立危险因素。

关键数值与推荐

  • 年龄、体重指数、颈围、PaCO2、FEV1、FEV1占预计值%、中重度OSA(AHI>15次/h)、mMRC、CAT、慢阻肺急性加重次数及住院次数,与OVS患者发生死亡相关(P<0.05)。

临床怎么用

  • 对OVS患者应关注高龄、低FEV1及反复慢阻肺急性加重等高死亡风险因素。
  • 在常规治疗基础上加用NIPPV可能有助于降低OVS患者心脑血管疾病相关死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the effect of noninvasive positive pressure ventilation(NIPPV) on all-cause mortality in patients with chronic obstructive pulmonary disease-obstructive sleep apnea overlap syndrome(OVS) through long-term follow-up. Methods: A total of 187 OVS patients were divided into the NIPPV group(n=92) and the non-NIPPV group(n=95). Of these, 85 males and 7 females were in the NIPPV group with an average age of (66.5±8.5) years(range 47-80 years); 89 males and 6 females were in the non-NIPPV group with an average age of (67.4±7.8) years(range 44-79 years). Follow-up was performed from enrolment with an average duration of 39(20, 51) months. The all-cause mortality was compared between the two groups. Result: There were no significant differences in their baseline clinical characteristics(all P>0.05), indicating that the data from the two groups were comparable. The Kaplan-Meier curve showed no difference in all-cause mortality between the two groups(log rank P=0.229). However, deaths from cardio-cerebrovascular diseases were higher in the non-NIPPV than in the NIPPV group(15.8% vs. 6.5%,P=0.045). Age, BMI, neck circumference, PaCO2, FEV1, FEV1%, moderate to severe OSA(AHI>15 events/h), mMRC, CAT, number of acute exacerbations of COPD and number of hospitalizations were associated with all-cause death in OVS patients; among which, age(HR 1.067, 95%CI 1.017-1.119, P=0.008), FEV1(HR 0.378, 95%CI 0.176-0.811, P=0.013), and number of COPD exacerbations(HR 1.298, 95%CI 1.102-1.530, P=0.002) were independent risk factors for all-cause mortality in OVS patients. Conclusions: The combination of NIPPV and conventional treatment may reduce cardio-cerebrovascular disease-related mortality in OVS patients. The deceased OVS patients had severe airflow limitation and mild to moderate OSA. Old age, low FEV1 and COPD exacerbations were independent risk factors for all-cause mortality in OVS patients. 目的: 通过长期随访探讨无创正压通气(NIPPV)对慢性阻塞性肺疾病-阻塞性睡眠呼吸暂停重叠综合征(OVS)患者全因死亡的影响。 方法: 前瞻性纳入OVS患者187例,将之分为NIPPV组和未使用NIPPV组。其中NIPPV组92例,男85例,女7例,年龄47~80(66.5±8.5)岁;未使用NPPV组95例,男89例,女6例,年龄45~79(67.4±7.8)岁。自入组后开始随访,平均随访39(20,51)个月,比较两组患者的全因死亡。 结果: 两组患者基线资料比较差异无显著性(均P>0.05),具有可比性。Kaplan-Meier曲线显示两组全因病死率无差异(log rank P=0.229),但未使用NIPPV组心脑血管疾病病死率更高(分别为15.8%、6.5%,P=0.045)。年龄、体重指数、颈围、PaCO2、FEV1、FEV1占预计值%、中重度OSA(AHI>15次/h)、mMRC、CAT、慢阻肺急性加重次数及住院次数,与OVS患者发生死亡相关(P<0.05)。其中,年龄(HR为1.067,95%CI:1.017~1.119,P=0.008)、FEV1(HR为0.378,95%CI:0.176~0.811,P=0.013)以及慢阻肺急性加重次数(HR为1.298,95%CI:1.102~1.530,P=0.002)是OVS患者死亡的独立危险因素。 结论: 在常规治疗基础上加用NIPPV可降低OVS患者因心脑血管疾病而死亡的风险;OVS死亡患者的气流受限严重,而OSA程度相对较轻;高龄、低FEV1以及慢阻肺急性加重次数是OVS患者死亡独立危险因素。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yue F, Yang HZ, Hao YY, et al. [A long-term follow-up study of noninvasive positive pressure ventilation on all-cause mortality in patients with chronic obstructive pulmonary disease-obstructive sleep apnea overlap syndrome]. Zhonghua Jie He He Hu Xi Za Zhi. 2023. PMID: 36990701. doi:10.3760/cma.j.cn112147-20220808-00663

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。